Management of Erectile Dysfunction: An Under-recognition of Hypertension

Koroglu G., KAYA SEZGİNER E., YILMAZ ORAL D., GÜR S.

CURRENT PHARMACEUTICAL DESIGN, vol.24, no.30, pp.3506-3519, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 24 Issue: 30
  • Publication Date: 2018
  • Doi Number: 10.2174/1381612824666180828104350
  • Journal Name: CURRENT PHARMACEUTICAL DESIGN
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.3506-3519
  • Keywords: Antihypertensive treatment, endothelial dysfunction, erectile dysfunction, hypertension, phosphodiesterase-5 inhibitors, high blood pressure, QUALITY-OF-LIFE, NITRIC-OXIDE SYNTHASE, PENILE CORPUS CAVERNOSUM, CARDIOVASCULAR RISK-FACTORS, PROGENITOR CELLS CORRELATE, AMBULATORY BLOOD-PRESSURE, II RECEPTOR-BLOCKER, C-REACTIVE PROTEIN, OXIDATIVE STRESS, ENDOTHELIAL FUNCTION
  • Ankara University Affiliated: Yes

Abstract

Background: Erectile dysfunction (ED) affects 30 million men in the US with a decrease in quality of life. Thirty percent of hypertensive men suffer from ED.